Sign In
Buy NNVC
$1.31
-0.0100 (-0.758%)
At Close: Jun 23, 2026
NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd
08:30am, Monday, 03'rd Nov 2025
SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs th
NanoViricides targets broad-spectrum virus threats – ICYMI
04:04pm, Friday, 31'st Oct 2025
NanoViricides (NYSE-A:NNVC) CEO Dr Anil Diwan talked with Proactive about the company's latest progress with its broad-spectrum antiviral candidate, NV-387. Dr Diwan confirmed that NV-387 demonstrated
Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive
08:45am, Wednesday, 29'th Oct 2025
SHELTON, CONNECTICUT / ACCESS Newswire / October 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), announced that Nanoviricides CEO Dr Anil Diwan joined Stev
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27
08:45am, Monday, 27'th Oct 2025
SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the
NanoViricides reports antiviral activity of NV-387 against measles in preclinical studies
09:17am, Wednesday, 22'nd Oct 2025
NanoViricides (NYSE-A:NNVC) said on Wednesday its experimental drug NV-387 showed strong activity against the measles virus in both cell culture studies and a humanized animal model. The company said
SHELTON, CONNECTICUT / ACCESS Newswire / October 22, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer:NNVC) (the "Company"), announced that its clinical lead drug NV-387 has shown stro
NanoViricides says lead drug NV-387 shows strong activity against Measles virus
09:11am, Monday, 20'th Oct 2025
NanoViricides (NYSE-A:NNVC) said on Monday its experimental antiviral drug NV-387 showed strong activity against the Measles virus in a humanized animal model, adding that it could be made available f
SHELTON, CT / ACCESS Newswire / October 20, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), announced that its clinical lead drug NV-387 has shown strong ac
SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the Company that explains
NanoViricides, Inc. Has Filed its Annual Report
08:45am, Tuesday, 30'th Sep 2025
Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage - NV-387 Could Become a Revolutionary Antiviral for Respiratory Viral Infections SHELTON, CONNECTICUT / ACCESS Newswire / September 30,
RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
08:30am, Thursday, 11'th Sep 2025
This release is being retransmitted for extra exposure to downstream sites. SHELTON, CT / ACCESS Newswire / September 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical st
NanoViricides says antiviral NV-387 may reduce cancer resurgence risk tied to viral infections
09:35am, Monday, 18'th Aug 2025
NanoViricides (NYSE-A:NNVC) said on Monday that its experimental broad-spectrum antiviral drug NV-387, now advancing into Phase II clinical trials, may help lower the risk of metastatic cancer returni
SHELTON, CONNECTICUT / ACCESS Newswire / August 18, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the deve
NanoViricides says antiviral candidate NV-387 could address global measles surge
09:33am, Wednesday, 30'th Jul 2025
NanoViricides (NYSE-A:NNVC) said on Wednesday that its antiviral candidate NV-387 could play a key role in addressing the growing number of measles cases globally, particularly in industrialized nati
Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides
08:30am, Wednesday, 30'th Jul 2025
SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of bro
